For optimal results, we recommend combining Semaglutide treatment with lifestyle modifications
"FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event" (Press release)
GLP-1 is released during digestion, binds to receptors that release insulin, and slows down stomach emptying
PlexusDx offers the Precision Peptide Genetic Test, which maps 14 metabolic pathways and identifies variants in GLP1R, GIPR, FTO, and MC4R genes that influence medication efficacy and side-effect risk
However, these compounded versions have been associated with serious health risks, including dosing errors, adverse reactions, and the presence of harmful impurities